1.59
+0.63%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vyome Holdings
From its filings with the US Securities and Exchange Commission
Vyome Holdings is based in San Clemente, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HIND. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $319,714 and a net loss of $10.3m. At that date it held total assets of $6.5m.
Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the “Merger”).
VB-1953 programs that are in development, and our pharmaceutical segment comprises our antifungal products.
MFW by over 75% and pain by 50%. We plan to conduct pivotal studies for VT-1953 for treatment of symptoms of malignant fungating wound.
The aim is to provide sufficient evidence of safety and efficacy before clinical trials in humans can begin.
It also binds at the interface of MD2-TLR immunomodulatory interaction, which can exert an anti-inflammatory effect in MFW.
In comparison, 4X higher concentration of metronidazole is needed to achieve the same level of activity (MIC50 metronidazole=2 μg/ml).
IL6 response, which was inhibited by VT-1953 in a concentration-dependent manner (See Figure 5d).
Quoted from its 10-K, filed 18 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 6 Oct 2016
- Employees
- 17
- Website
- reshapelifesciences.com/obalon ↗
- Head office
- 1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Krishna GuptaChairman of the Board, since 2025
- Mr. Venkateswarlu NelabhotlaChief Executive Officer, Director, since 2025
- Mr. Robert DickeyInterim Chief Financial Officer
- Mr. Mohanjit JollyDirector
- Mr. Stash PomichterDirector
- Mr. Shiladitya SenguptaDirector
- Mr. John TincoffDirector
- Ms. Lori McdougalIndependent Director$37,782
- Dr. Arda MinocherhomjeeIndependent Director$44,719
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vyome Holdings Inc employs 17 full-time employees in Health Care Equipment & Supplies.
- The company's immuno-inflammatory assets advance development in Health Care.
- Vyome Holdings Inc identifies additional opportunities in Health Care sector.
Weaknesses
- Vyome Holdings Inc has a small workforce of 17 employees.
- The company's IPO was in 2016, indicating limited market presence.
- ReShape Lifesciences Inc. rebranded to Vyome Holdings Inc. in 2016.
Opportunities
- Vyome Holdings Inc can expand its immuno-inflammatory assets in Health Care.
- The Health Care Equipment & Supplies industry offers growth potential.
- Vyome Holdings Inc can identify new opportunities in Health Care sector.
Threats
- Vyome Holdings Inc faces competition in Health Care Equipment & Supplies.
- The Health Care sector has regulatory challenges for new assets.
- Vyome Holdings Inc's small size may limit market reach.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.